The latest announcement is out from SWK Holdings Corporation (SWKH).
Enteris Biopharma granted AptarGroup an exclusive option to acquire certain Enteris assets, with the option valid until January 2026. Aptar paid a low-single digit million option fee and must make minimum annual revenue payments for 2024 and 2025. If Aptar exercises the option, they will pay a $6 million fee plus additional costs, with potential increases based on annual growth rates. The agreement includes standard clauses and commitments to maintain business operations, with the possibility of termination under certain conditions. This deal has forward-looking statements and is subject to risks detailed in SWK’s SEC filings.
Learn more about SWKH stock on TipRanks’ Stock Analysis page.
